ArticleVaccine: X2023
Production of recombinant lumpy skin disease virus A27L and L1R proteins for application in diagnostics and vaccine development.
Article in Vaccine: X, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Comparison of multiple antigens for use in indirect ELISAs for detection of anti-capripoxvirus antibodies in sheep, goats, and cattle.Journal of clinical microbiology · 2026Article
- Evaluation of recombinant extracellular enveloped virion protein candidates for the detection of serological responses to lumpy skin disease virus in cattle.The veterinary quarterly · 2025Article
- Novel multi-epitope vaccine candidate for lumpy skin disease: Computational design and recombinant expression.Veterinary world · 2025Article
- Which Proteins? The Challenge of Identifying the Protective Antigens for Next-Generation Capripoxvirus Vaccines.Vaccines · 2025Review
- Molecular Detection, Seroprevalence and Biochemical Analysis of Lumpy Skin Disease Virus.Viruses · 2025Article
- Lumpy skin disease: A growing threat to the global livestock industry.Open veterinary journal · 2025Review
- Development and validation of recombinant A27L based indirect-ELISA for Sheeppox and Goatpox disease in India.Veterinary research communications · 2025Article
- Review
- Two proteins, one goal: ELISAs based on p32 and L1R for LSDV antibodies detection.Frontiers in veterinary science · 2025Article
- Lumpy Skin Disease: Insights into Molecular Pathogenesis and Control Strategies.Veterinary sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccination using live attenuated vaccines (LAVs) is considered the most effective method for control of lumpy skin disease (LSD). However, this method is limited by safety concerns, with reports of adverse reactions following vaccination. This study evaluates A27L and L1R which are essential proteins for virus attachment and membrane fusion as recombinant sub-unit vaccines against LSD. These proteins were recombinantly expressed in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.